You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
The innovative medical services company is making adjustments to improve the bottom line.
Fool.com contributor Parkev Tatevosian offers investors an earnings review of Invitae (NVTA -94.44%) and lets you know if the beaten-down growth stock is a buy.
*Stock prices used were the afternoon prices of Aug. 8, 2023. The video was published on Aug. 10, 2023.
Parkev Tatevosian, CFA has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Invitae. The Motley Fool has a disclosure policy. Parkev Tatevosian is an affiliate of The Motley Fool and may be compensated for promoting its services. If you choose to subscribe through his link, he will earn some extra money that supports his channel. His opinions remain his own and are unaffected by The Motley Fool.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
